BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38685615)

  • 1. Marked eosinophilic atypia in a patient with asthma and myeloid/lymphoid neoplasm with FIP1L1::PDGFRA fusion.
    Deb PQ; Li L
    Br J Haematol; 2024 Apr; ():. PubMed ID: 38685615
    [No Abstract]   [Full Text] [Related]  

  • 2. Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.
    Akiely R; Almasri F; Almasri N; Abu-Ghosh A
    Front Pediatr; 2022; 10():1059527. PubMed ID: 36589160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
    Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
    Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.
    Burgstaller S; Kreil S; Waghorn K; Metzgeroth G; Preudhomme C; Zoi K; White H; Cilloni D; Zoi C; Brito-Babapulle F; Walz C; Reiter A; Cross NC
    Leukemia; 2007 Dec; 21(12):2428-32. PubMed ID: 17914408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
    Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
    Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
    Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
    Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia.
    Cools J; Stover EH; Gilliland DG
    Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.
    Yang Y; Lin H; Du Z; Hu R; Tang Y; Liang X; Sun J; Tan Y
    Oncol Lett; 2020 May; 19(5):3587-3592. PubMed ID: 32269633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
    Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
    Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
    Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
    Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.
    Gorantla SP; Zirlik K; Reiter A; Yu C; Illert AL; Von Bubnoff N; Duyster J
    Leukemia; 2015 Aug; 29(8):1763-70. PubMed ID: 25761934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
    Tang TC; Chang H; Chuang WY
    Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
    Jovanovic JV; Score J; Waghorn K; Cilloni D; Gottardi E; Metzgeroth G; Erben P; Popp H; Walz C; Hochhaus A; Roche-Lestienne C; Preudhomme C; Solomon E; Apperley J; Rondoni M; Ottaviani E; Martinelli G; Brito-Babapulle F; Saglio G; Hehlmann R; Cross NC; Reiter A; Grimwade D
    Blood; 2007 Jun; 109(11):4635-40. PubMed ID: 17299092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases.
    Bellani V; Croci GA; Bucelli C; Maronese CA; Alberti S; Iurlo A; Cattaneo D
    J Dermatol; 2023 Oct; 50(10):1330-1334. PubMed ID: 37248740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.
    Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T
    Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
    Capovilla M; Cayuela JM; Bilhou-Nabera C; Gardin C; Letestu R; Baran-Marzak F; Fenaux P; Martin A
    Eur J Haematol; 2008 Jan; 80(1):81-6. PubMed ID: 18028420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.